Recommendations of the Crohn’s Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn’s disease

Eglinton, 2012, The spectrum of perianal Crohn’s disease in a population-based cohort, Dis Colon Rectum, 55, 773, 10.1097/DCR.0b013e31825228b0 Schwartz, 2002, The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology., 122, 875, 10.1053/gast.2002.32362 Chaparro, 2012, Epidemiological study of perianal fistulas in patients with Crohn´s disease, J Crohns Colitis, 6, P235 Alós, 2014, Tratamiento de la enfermedad perianal Ratto, 2000, How can the assessment of fistula-inano be improved?, Dis Colon Rectum., 43, 1375, 10.1007/BF02236633 Gionchetti, 2017, 3rd European evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations, J Crohns Colitis., 11, 135, 10.1093/ecco-jcc/jjw169 Haggett, 1995, Pelvic and perineal complications of Crohn’s disease: assessment using magnetic resonance imaging, Gut., 36, 407, 10.1136/gut.36.3.407 Ong, 2015, Guidelines for imaging of Crohn´s perianal fistulizing disease, Infamm Bowel Dis, 21, 731, 10.1097/MIB.0000000000000367 Panes, 2013, Imaging techiques for assement of inflammatory bowel disease : Joint ECCO and ESGAR evidence-based consensus, J Crohns Colitis, 7, 556, 10.1016/j.crohns.2013.02.020 Schwartz, 2001, A comparision of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn´s perianal fistulas, Gastroenterology, 121, 1064, 10.1053/gast.2001.28676 Van Assche, 2003, Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn´s disease, Am J Gastroenetrol, 98, 332, 10.1016/S0002-9270(02)05909-9 Gecse, 2014, A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulizing Crohn´s disease, Gut, 63, 1381, 10.1136/gutjnl-2013-306709 Law, 1989, Anal endosonography: technique and normal anatomy, Gastrointest Radiol, 14, 349, 10.1007/BF01889235 Navarro-Luna, 2004, Ultrasound study of anal fistulas with hydrogen peroxide enhancement, Dis Colon Rectum, 47, 108, 10.1007/s10350-003-0015-8 Wedemeyer, 2004, Transcutaneos perianal sonography: a sensitive method for the detection of perianal inflammatory lesions in Crohn´s disease, World J Gastrioenterol, 10, 2859, 10.3748/wjg.v10.i19.2859 Hughes, 1978, Surgical pathology and management of anorectal Crohn’s disease, J R Soc Med., 71, 644, 10.1177/014107687807100904 Irvine, 1995, Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index, J Clin Gastroenterol, 20, 27, 10.1097/00004836-199501000-00008 Sandborn, 2003, American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease, Gastroenterology., 125, 1508, 10.1016/j.gastro.2003.08.025 Parks, 1976, A classification of fistula in ano, Br J Surg., 63, 1, 10.1002/bjs.1800630102 Spencer, 1998, Outcome after surgery for perianal fistula: predictive value of MR imaging, Am J Roentgenol, 171, 403, 10.2214/ajr.171.2.9694464 Ng, 2009, Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn’s perineal fistulas, Am J Gastroenterol, 104, 2973, 10.1038/ajg.2009.509 Allan, 1992, Clinical index to quantitate symptoms of perianal Crohn’s disease, Dis Colon Rectum, 35, 656, 10.1007/BF02053756 Steinhart, 2019, Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease: the Toronto consensus, Inflamm Bowel Dis, 25, 1, 10.1093/ibd/izy247 Vermeire, 2007, Perianal Crohn’s disease: classification and clinical evaluation, Dig Liver Dis., 39, 959, 10.1016/j.dld.2007.07.153 Nielsen, 2008, Drug insight: aminosalicylates for the treatment of IBD, Nat Clin Pract Gastroenterol Hepatol, 4, 160, 10.1038/ncpgasthep0696 Jones, 1966, Corticosteroids and corticotrophin in the treatment of Crohn’s disease, Gut, 7, 181, 10.1136/gut.7.2.181 Juncadella, 2015, Perianal Crohn’s disease: a review, Postgrad Med., 127, 266, 10.1080/00325481.2015.1023160 Bernstein, 1980, Healing of perineal Crohn’s disease with metronidazole, Gastroenterology., 79, 357, 10.1016/0016-5085(80)90155-9 Thia, 2009, Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study, Inflamm Bowel Dis, 15, 17, 10.1002/ibd.20608 Khan, 2011, Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis, Am J Gastroenterol., 106, 661, 10.1038/ajg.2011.72 Wu, 2015, Meta-analysis of ciprofloxacin in treatment of Crohn’s disease, Biomed Rep., 3, 70, 10.3892/br.2014.368 Dejaco, 2003, Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease, Aliment Pharmacol Ther, 18, 1113, 10.1046/j.1365-2036.2003.01793.x West, 2004, Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study, Aliment Pharmacol Ther, 20, 1329, 10.1111/j.1365-2036.2004.02247.x Dewint, 2014, Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI), Gut, 63, 292, 10.1136/gutjnl-2013-304488 Kariyawasam, 2014, Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn’s disease, Inflamm Bowel Dis., 20, 1382, 10.1097/MIB.0000000000000119 Present, 1980, Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study, N Engl J Med, 302, 981, 10.1056/NEJM198005013021801 Korelitz, 1985, Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease, Dig Dis Sci, 30, 58, 10.1007/BF01318372 O’Brien, 1991, Use of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease, Gastroenterology, 101, 39, 10.1016/0016-5085(91)90457-V Markowitz, 1990, Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease, Gastroenterology, 99, 1347, 10.1016/0016-5085(90)91160-8 Pearson, 1995, Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis, Ann Int Med, 123, 132, 10.7326/0003-4819-123-2-199507150-00009 Prefontaine, 2010, Azathioprine and 6-mercaptopurine for induction of remission in Crohn’s disease, Cochrane Database Syst Rev, 10.1002/14651858.CD000545.pub3 Chande, 2013, Azathioprine and 6-mercaptopurine for induction of remission in Crohn’s disease, Cochrane Database Syst Rev., 30, 10.1002/14651858.CD000545.pub4 McDonald, 2005, Cyclosporine for induction of remission in Crohn’s disease, Cochrane Database Syst Rev, 2 McSharry, 2011, Systematic review: the role of tacrolimus in the management of Crohn’s disease, Aliment Pharmacol Ther., 34, 1282, 10.1111/j.1365-2036.2011.04873.x Sandborn, 2003, Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial, Gastroenterology, 125, 380, 10.1016/S0016-5085(03)00877-1 González Lama, 2004, Long-term oral tacrolimus in refractory to infliximab fistulizing Crohn’s disease: comments from Spanish experience, Gastroenterology., 126, 942, 10.1053/j.gastro.2004.01.046 Lowry, 1999, Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae, Inflamm Bowel Dis., 5, 239, 10.1097/00054725-199911000-00001 Ford, 2011, Efficacy of biological therapies in inflammatory bowel disease: systemic review and meta-analysis, Am J Gastroenterol, 106, 644, 10.1038/ajg.2011.73 Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn’s disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804 Sands, 2004, Infliximab maintenance therapy for fistulizing Crohn’s disease, N Engl J Med, 350, 876, 10.1056/NEJMoa030815 Sands, 2004, ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study, Clin Gastroenterol Hepatol, 2, 912, 10.1016/S1542-3565(04)00414-8 Lichtenstein, 2005, Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn’s disease, Gastroenterology, 128, 862, 10.1053/j.gastro.2005.01.048 Farrell, 2000, Clinical experience with infliximab therapy in 100 patients with Crohn’s disease, Am J Gastroenterol, 95, 3490, 10.1111/j.1572-0241.2000.03366.x Ricart, 2001, Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients, Am J Gastroenterol, 96, 722, 10.1111/j.1572-0241.2001.03612.x Colombel, 2007, Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial, Gastroenterology, 132, 52, 10.1053/j.gastro.2006.11.041 Lichtiger, 2010, The CHOICE trial: adalimumab demonstrates safety, fistula healing improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior to infliximab therapy, Aliment Pharmacol Ther, 32, 1228, 10.1111/j.1365-2036.2010.04466.x Hanauer, 2006, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial, Gastroenterology, 130, 323, 10.1053/j.gastro.2005.11.030 Sandborn, 2007, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial, Ann Intern Med, 146, 829, 10.7326/0003-4819-146-12-200706190-00159 Hinojosa, 2007, Aliment Pharmacol Ther., 25, 409, 10.1111/j.1365-2036.2006.03232.x Echarri, 2010, Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn’s disease patients with infliximab failure, J Crohns Colitis., 4, 654, 10.1016/j.crohns.2010.07.012 Castaño-Milla, 2015, Effectiveness of adalimumab in perianal fistulas in crohn’s disease patients naive to anti-TNF therapy, J Clin Gastroenterol., 49, 34, 10.1097/MCG.0000000000000169 Sandborn, 2007, Certolizumab pegol for the treatment of Crohn’s disease, N Engl J Med, 357, 228, 10.1056/NEJMoa067594 Schreiber, 2007, Maintenance therapy with certolizumab pegol for Crohn’s disease, N Engl J Med, 357, 239, 10.1056/NEJMoa062897 Schreiber, 2011, Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo-controlled study, Aliment Pharmacol Ther, 33, 185, 10.1111/j.1365-2036.2010.04509.x Bouguen, 2013, Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab, Clin Gastroenterol Hepatol, 8, 975, 10.1016/j.cgh.2012.12.042 Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn’s disease, N Engl J Med, 362, 1383, 10.1056/NEJMoa0904492 Sandborn, 2013, GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease, N Engl J Med, 369, 711, 10.1056/NEJMoa1215739 Bermejo, 2018, Pharmacological approach to the management of Crohn’s disease patients with perianal disease, Drugs., 78, 1, 10.1007/s40265-017-0842-x Feagan, 2018, Efficacy of vedolizumab in fistulising Crohn’s disease: exploratory analyses of data from GEMINI 2, Journal of Crohn’s and Colitis, 621, 10.1093/ecco-jcc/jjy019 Dulai, 2016, The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium, Am J Gastroenterol., 111, 1147, 10.1038/ajg.2016.236 Tadbiri, 2017, Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a posthoc analysis of the OBSERV-IBD cohort from the GETAID, J Crohn’s Collitis., 11, S42, 10.1093/ecco-jcc/jjx002.062 Biron, 2019, DOP78 Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study, Journal of Crohn’s and Colitis, 13, S077, 10.1093/ecco-jcc/jjy222.112 Sands, 2017, Fistula healing in pivotal studies of ustekinumab in Crohn’s disease, Gastroenterology., 152, S185, 10.1016/S0016-5085(17)30930-7 Feagan, 2016, Ustekinumab as induction and maintenance therapy for Crohn’s disease, N Engl J Med., 375, 1946, 10.1056/NEJMoa1602773 Sandborn, 2012, Ustekinumab induction and maintenance therapy in refractory Crohn’s disease, N Engl J Med., 367, 1519, 10.1056/NEJMoa1203572 Khorrami, 2016, Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort, Inflamm Bowel Dis., 22, 1662, 10.1097/MIB.0000000000000842 Biron, 2019, DOP74 Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study, J Crohn’s Colitis, 13, S074, 10.1093/ecco-jcc/jjy222.108 De Groof, 2016, Systematic review of evidence and consensus on perianal fistula: an analysis of national and international guidelines, Colorectal Dis., 18, O119, 10.1111/codi.13286 Gecse, 2016, Results of the Fifth Scientific Workshop of the ECCO [II]: clinical aspects of perianal fistulising Crohn’s disease-the unmet needs, J Crohns Colitis., 10, 758, 10.1093/ecco-jcc/jjw039 Lee, 2017, Surgical management of fistulating perianal Crohn’s disease: a UK survey, Colorectal Dis., 19, 266, 10.1111/codi.13462 Panés, 2017, Perianal fistulizing Crohn´s disease: pathogenesis, diagnosis and therapy, Nat Rev Gastroenterol Hepatol, 14, 652, 10.1038/nrgastro.2017.104 Soltani, 2010, Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano, Dis Colon Rectum, 53, 486, 10.1007/DCR.0b013e3181ce8b01 Robertson, 1998, Cutaneous advancement flap closure: alternative method for treatment of complicated anal fistulas, Dis Colon Rectum, 41, 884, 10.1007/BF02235371 Adegbola, 2018, Symptom amelioration in Crohn’s perianal fistulas using video assisted anal fistula treatment (VAAFT), J Crohns Colitis., 12, 1067 Topstad, 2003, Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience, Dis Colon Rectum, 46, 577, 10.1007/s10350-004-6611-4 Schwartz, 2017, Comparison of health care utilization and costs between patients with perianal fistulizing crohn’s disease treated with biologics with or without previous seton placement, Inflamm Bowel Dis., 23, 1860, 10.1097/MIB.0000000000001243 Lee, 2017, ACPGBI Perianal Crohn’s Disease Group. Association of Coloproctology of Great Britain and Ireland consensus exercise on surgical management of fistulating perianal Crohn’s disease, Colorectal Dis., 19, 418, 10.1111/codi.13672 Martí-Gallostra, 2017, The role of a defunctioning stoma for colonic and perianal Crohn’s disease in the biological era, Scand J Gastroenterol., 52, 251, 10.1080/00365521.2016.1205127 Milito, 2017, Surgical treatment of rectovaginal fistula in Crohn’s disease: a tertiary center experience, Surg Technol Int., 30, 113 Rottoli, 2018, Gracilis muscle transposition for the treatment of recurrent rectovaginal and pouch-vaginal fistula: is Crohn’s disease a risk factor for failure? A prospective cohort study, Updates Surg., 70, 485, 10.1007/s13304-018-0558-9 Lindsey, 2002, A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula, Dis Colon Rectum, 45, 1608, 10.1007/s10350-004-7247-0 Norderval, 2018, Efficacy of autologous fat graft injection in the treatment of anovaginal fistulas, Tech Coloproctol., 22, 45, 10.1007/s10151-017-1739-0 Wilhelm, 2017, Five years of experience with the FiLaC™ laser for fistula-in-ano management: long-term follow-up from a single institution, Tech Coloproctol, 21, 269, 10.1007/s10151-017-1599-7 Lichtiger, 2001, Healing of perianal fistulae by local injection of antibody to TNF, Gastroenterology, 120, A621, 10.1016/S0016-5085(01)83091-2 Alessandroni, 2011, Local injection of infliximab in severe fistulating perianal Crohn’s disease: an open uncontrolled study, Tech Coloproctol, 15, 407, 10.1007/s10151-011-0759-4 Asteria, 2006, Treatment of perianal fistulas in Crohn’s disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study, Scand J Gastroenterol, 41, 1064, 10.1080/00365520600609941 Poggioli, 2005, Campieri M.Local injection of Infliximab for the treatment of perianal Crohn’s disease, Dis Colon Rectum., 48, 768, 10.1007/s10350-004-0832-4 Poggioli, 2010, Local injection of adalimumab for perianal Crohn’s disease: better than infliximab?, Inflamm Bowel Dis, 16, 1631, 10.1002/ibd.21210 Laureti, 2012, Combination of surgical therapy and local injections of adalimumab in treatment of complex perianal Crohn’s disease, J Crohn’s Colitis, 6, S166, 10.1016/S1873-9946(12)60412-7 Tonelli, 2012, Effectiveness and safety of local adalimumab injection in patients with fistulizig perianal Crohn’s disease: a pilot study, Dis Colon Rectum., 55, 870, 10.1097/DCR.0b013e31825af532 Panes, 2010, Stem cell treatment for Crohn’s disease, Expert Rev Clin Immunol, 6, 597, 10.1586/eci.10.27 Garcia-Olmo, 2005, A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation, Dis Colon Rectum., 48, 1416, 10.1007/s10350-005-0052-6 Garcia-Olmo, 2009, Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial, Dis Colon Rectum, 52, 79, 10.1007/DCR.0b013e3181973487 Guadalajara, 2012, Long-term followup of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas, Int J Colorectal Dis., 27, 595, 10.1007/s00384-011-1350-1 Panés, 2016, Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial, Lancet, 388, 1281, 10.1016/S0140-6736(16)31203-X Panés, 2018, Gastroenterology. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease, Gastroenterology, 154, 1334, 10.1053/j.gastro.2017.12.020 Lavy, 1994, Hyperbaric oxygen for perianal Crohn’s disease, J Clin Gastroenterol., 19, 202, 10.1097/00004836-199410000-00006 Colombel, 1995, Hyperbaric oxygenation in severe perineal Crohn’s disease, Dis Colon Rectum, 38, 609, 10.1007/BF02054120